Somewhat Favorable News Coverage Somewhat Unlikely to Impact Acceleron Pharma (XLRN) Share Price
News stories about Acceleron Pharma (NASDAQ:XLRN) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acceleron Pharma earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.8108411322156 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several equities research analysts recently issued reports on XLRN shares. Credit Suisse Group set a $51.00 price objective on shares of Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, November 14th. ValuEngine lowered shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. HC Wainwright started coverage on shares of Acceleron Pharma in a research note on Thursday, October 12th. They issued a “buy” rating and a $57.00 price objective for the company. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Finally, BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $44.81.
Acceleron Pharma (XLRN) opened at $42.35 on Friday. The company has a market cap of $1,870.00, a price-to-earnings ratio of -16.41 and a beta of 1.59. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $46.93.
In other news, Director Jean George sold 105,122 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the transaction, the director now owns 1,250 shares in the company, valued at approximately $44,662.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Christopher Rovaldi sold 2,266 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.42, for a total transaction of $96,123.72. Following the transaction, the senior vice president now owns 52,977 shares in the company, valued at approximately $2,247,284.34. The disclosure for this sale can be found here. Insiders sold a total of 146,021 shares of company stock worth $5,529,598 in the last quarter. Insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-acceleron-pharma-xlrn-share-price/1813370.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.